drugset / Trial / NCT00636155
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to see if the investigational drug EL625, when combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in Persistent Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Timeline
- Start
- 2008-02
- Primary completion
- 2011-08
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cenersen | Antisense oligonucleotide | 2.4 mg/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |